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Human stem cell research is at the forefront of ethical
debate, perhaps because of the potential of these cells to
effect biological change. In addition to the well-known
controversy concerning the permissibility of deriving stem
cells from human embryos, the question of whether
experiments involving manipulation of cells in this domain
should be constrained by species boundaries between the
human and the nonhuman animals has arisen. Progressive
accomplishments in scientific discovery and technology have
initiated distinct lines of discussion regarding hybrid and
chimera regulations: (1) If embryonic stem cell research is
legal and ethically acceptable, how will the materials for
study or therapy be obtained? (2) Does inducible pluripo-
tency of differentiated cells circumvent the ethical chal-
lenge of obtaining embryonic material? (3) Is it ethically
acceptable to utilize hybrids and chimeras of human and⁎ Corresponding author. The Biomedical Research Centre, Univer-
sity of British Columbia, 2222 Health Sciences Mall, Vancouver,
British Columbia, Canada V6T 1Z3. Fax: +1 604 822 7815.
E-mail addresses: sbordet@blue-hf.com (S. Bordet),
bennett@brc.ubc.ca (J. Bennett), bartha.knoppers@mcgill.ca
(B.M. Knoppers), Kelly@brc.ubc.ca, kelly@brc.ubc.ca
(K.M. McNagny).
1 These authors contributed equally in the preparation of this
manuscript.
1873-5061/$ – see front matter © 2009 Elsevier B.V. All rights reserved
doi:10.1016/j.scr.2009.10.002nonhuman cells or tissues for research purposes? (4) What
legal status and protection are afforded to the resulting
individual following such experimentation and therapy? The
debate has been further stimulated by the derivation of stem
cell lines from so-called qcybridq embryos (Chen et al.,
2003), and the creation of qchimerasq involving the intro-
duction of human stem cells into animal embryos (Muotri et
al., 2005). This paper describes the current regulation
scheme for human–animal chimeras in Canada, with empha-
sis on its implications for stem cell research.
Chimeras
What are chimeras?
The original Chimera was a creature from Greek mythology,
which had the head and thorax of a lion, central body
segments of a goat in the middle, and posterior of a snake. Its
name has, by extension, been used to describe a variety of
interspecies mixtures. There seems to be no universally
accepted nomenclature for such mixtures at the moment
(Greely, 2003; Hynes, 2007). In this paper, qchimeraq is used
to refer to the being that results from the introduction of
cells—in this case, stem cells, inducible pluripotent cells
(iPS), or products of nuclear transfer approaches of one
species into an organism of a different species. This
definition is somewhat broader than that presently found
in Canadian legislation because it specifically addresses the.
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species. Where relevant, the differences will be discussed.
Experimental uses of chimeras
Key diseases identified as potential targets for stem cell-
related therapy include central nervous system disorders
such as Alzheimer’s, Lou Gehrig’s (ALS), acute spinal cord
injury, and multiple sclerosis, as well as diabetes, cardiac
muscle loss, and other muscle dysfunction. Human–animal
chimeras have been used in the laboratory for years (McCune
et al., 1988), without apparently causing much debate with
respect to species mixtures. Some animal experiments have
received higher profile publicity and raised concerns about
similar manipulations involving human biological material
(Marshall, 1999). In one example, goat and sheep embryos
were fused at the blastocyst stage, resulting in a chimeric
animal named “Geep,” with sheep or goat characteristics in
different parts of its body (Fehilly et al., 1984). In another,
the transplantation of portions of quail brains into chickens,
and vice versa, caused the manifestation of some behaviour
typical of one species in the other (Balaban, 1997). No one
has yet published papers describing similar experiments
involving biological material from human beings. However, a
request for ethical guidance by Irving Weissman at Stanford
University regarding his plan to create a mouse with a brain
mostly composed of human neurons prompted a comprehen-
sive discussion in the scientific literature and the press
(Begley, 2005; Greely et al., 2007).
Nonetheless, chimeras involving human biological mate-
rials are used in various fields, including stem cell research.
There is general public and legal acceptance of solid organ
transplantation, as well as cellular transplants such as bone
marrow inclusive of hematopoietic stem cells. Efforts to
increase the resource pool of organs available for transplan-
tation spurred development of the so-called “humanized”
pigs which resulted from transgenic approaches at cell
surface molecule modifications (Buhler et al., 1999). Such
approaches require extensive laboratory testing to assess
function and feasibility of the therapy before introduction in
the clinic, always in animal models.
There are a series of steps involved in laboratory
development of techniques and therapies that follow the
scientific method and maintain rigor within the field.
Nonhuman cells, often mouse derived, are manipulated and
differentiated in vitro, and then subsequently injected in
vivo to assess their ability to repair or restore function in a
disease model. Human cells are then manipulated in vitro
using optimized methods developed in nonhuman studies.
The most effective preclinical assessment of therapeutic
feasibility involves transplantation of human-derived cells
into animal models to assess functional capacity and,
therefore, the creation of chimeras. The availability of
primary or new lines of embryonic stem cells is a major
challenge for these research streams, prompting exploration
of alternative techniques for securing cell material, such as
somatic cell nuclear transfer techniques (SCNT) in which the
nucleus of one species may be transferred in to amore readily
available oocyte of another species. To date, these techni-
ques have not successfully replicated the biological potential
of stem cells, possibly due to species specific differences in
epigenetic control of gene expression (methylation/demethylation) (Chung et al., 2009). A comprehensive
discussion of ethical and legal considerations regarding
cytoplasmic hybrid and animal–human combination research
in Canada has been previously funded by the Stem Cell
Network of Canada (Ogbogu et al., 2008; Bordet et al., 2007).
It is at this stage that laboratory development of stem cell
therapies potentially stalls due to restrictions on chimera
and hybrid generation. Interestingly, many of the pressures
for pursuing new organ transplantation approaches, such as
limited access to donor material, similarly affect the future
of human embryonic stem cell work. Some verification
protocols involve the injection of human stem cells into
animals to verify pluripotency (Conrad et al., 2008). The
insertion of human stem cells into animals at early stages of
development is also used to study their differentiation,
migration, and function (Muotri et al., 2005; Conrad et al.,
2008), and can result in animals in which a large proportion
of cells in specific tissues are human. These are useful as
models to study human disease and develop drugs or other
treatments (McCune et al., 1988), and could be used as
sources of cells, tissues, or organs for xenotransplantation. It
is tempting to speculate about the future efforts at
verification of pluripotency and function in the research
process and the rigor that may be lost in stem cell research if
specific steps in the scientific method are restricted. Of all
the concerns about chimeric experiments, the target tissue
appears to be of most consequence. Various guidelines set
out specific restrictions on germline or CNS contributions,
and it will be necessary to consistently specify which assays
are required as part of the development of every stem cell
therapeutic approach. It is ironic that experiments in which
we will learn of the usefulness of stem cells as an approach
to therapy could also reveal contributions to prohibited
target tissues.
Regulation of human–animal chimeras in Canada
A primary goal of stem cell research is to produce biological
material that can be used in regenerative medicine. The use
of animal stem cells or tissues derived from stem cell
technology in humans will not be considered here, although
such experiments have been carried out in other countries
(Fink et al., 2000). This would be considered allotransplan-
tation or xenotransplantation, subject to (among other
regulations) the clinical trial requirements of the Food and
Drugs Act. While Canada has considered the adoption of
specific standards for xenotransplantation in the past
(Health-Canada, 1999), and may adopt such standards in
the future, this has not yet occurred. For this reason, the
focus here will be on the federal regulation of experimental
manipulations involving laboratory human–animal chimeras.
The most relevant regulatory instruments in Canada are
the Assisted Human Reproduction Act (Department of
Justice, Canada, 2004) (the qAct”) and the Updated Guide-
lines for Human Pluripotent Stem Cell Research, June 29,
2007 (the qGuidelinesq) (CIHR, 2007), both of which apply to
experimental human–animal interspecies mixtures used in
stem cell research. Furthermore, chimera research is subject
to the general laws and rules applicable to all research,
including those involving research with human subjects,
biosafety, animal care and handling, environmental protec-
tion, and laboratory or municipal requirements.
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The Act is specifically aimed at regulating human reproduc-
tion and related research involving embryos, prohibiting
some practices (such as cloning, creating embryos for
research, or selecting the sex of one’s offspring for
nonmedical reasons) and controlling others such as the
creation, storage, manipulation, and use of embryos through
a licensing system administered by the Assisted Human
Reproduction Agency.
Although the Act makes it an offence to knowingly qcreate
a chimera, or transplant a chimera into either a human being
or a nonhuman life formq (Section 5(l) (i) of the Act
(Department of Justice, Canada, 2004)), its definition of a
chimera is quite narrow. The Act defines a chimera as either
(a) an embryo into which a cell of any nonhuman life form has
been introduced; or (b) an embryo that consists of cells of
more than one embryo, fetus, or human being. The
prohibition targets the creation or transplantation of
chimeras made with human embryos, and does not apply to
chimeras made at the fetal, or later, stages. As a result, it
leaves open the possibility of cell therapy and tissue or organ
transplants at these stages. It also specifically prohibits
cellular therapy at early developmental stages even in cases
where, for example, sibling stem cells are available. In
addition, because qembryoq in the Act refers to a human
embryo (Section 3 of the Act, (Department of Justice,
Canada, 2004)), the Act does not address the question of
chimeras made by introducing human cells into animals, at
any stage of development. This is a striking difference in
Canadian law as compared to other countries. Alternative
approaches to regulation of similar activities have been
considered in the United States (United States. Human
Chimera Prohibition Act of 2005, S. 659 109th Congr., 2005),
but the corresponding Act was never passed.
There are penalties set out in the Act for violation of the
regulations. Anyone convicted of violating the prohibition
against making or transplanting a chimera could face a fine
not exceeding $500,000 and imprisonment for a term not
exceeding 10 years, or both, if convicted on indictment; a
summary conviction will entail a fine of up to $250,000,
imprisonment for a period not exceeding 4 years, or both
(Section 60 of the Act (Department of Justice, Canada,
2004)). There is no discussion about limitations on future
research activities following violations.The Guidelines
It thus appears that a number of possible human–animal
chimeras are not prohibited or otherwise regulated by the
Act. Other sources of regulation exist, however. Federal
agencies do have the power to impose conditions and
restrictions on recipients of research grants. This power
has been used to foster the application of safety rules for
biological research (Public Health Agency of Canada, 2004),
for example, as well as ethical rules regarding research
conducted with human beings and human tissue (Medical
Research Council (Canada), 2003). The three agencies mainly
responsible for funding scientific research in Canada (Cana-
dian Institutes of Health Research (CIHR), Natural Sciences
and Engineering Research Council of Canada (NSERC), SocialSciences and Humanities Research Council of Canada
(SSHRC)) have adopted standards aimed at ensuring the
safe and ethical conduct of human stem cell research (here,
the “Guidelines”) which contain provisions regulating some
research with chimeras. These guidelines do not place
absolute legal restrictions on work that may be performed
in Canada, but rather, seek to regulate activities funded by
public monies under the auspices of these agencies. The
Guidelines include rules applicable to permissible stem cell
research, including review by a stem cell oversight commit-
tee (“SCOC”) and disclosure or avoidance of conflicts of
interest. These policies also apply to all stem cell research
involving chimeras and hybrids.
In addition to these general requirements, the Guide-
lines provide specific examples of permitted and prohibited
research relevant to chimera-specific activities. Research
in which human or nonhuman embryonic stem cells or
embryonic germ cells or other cells that are likely to be
pluripotent are combined with a human embryo or a
human fetus is prohibited (Sections 8.2.4 and 2.4.5 of the
Stem Cell Guidelines (CIHR, 2007)). Thus, the Stem Cell
Guidelines not only parallel the prohibitions found in the
Act, but go further to ban the creation of a human chimera
at a later developmental stage than the Act. The same is
true of research in which human embryonic stem cells or
embryonic germ cells or other cells that are likely to be
pluripotent are combined with a nonhuman embryo or a
nonhuman fetus (Sections 8.2.6 and 8.2.7 of the Stem Cell
Guidelines (CIHR, 2007)).
With regard to this point, it is noteworthy that during
routine bone marrow transplantation, several laboratories
have reported the rare contribution of donor bone marrow
cells to the neural cell pool (Purkinji cells are a recent
example) (Johansson et al., 2008). These events usually
occur at low frequencies and are unusual in that they involve
cell fusion rather than straightforward engraftment, but
they offer an interesting example of the complexities of this
issue. Human cord blood and bone marrow stem cell
transplantation into immunocompromised mice is the most
widely used preclinical model for evaluating the quality of
human stem cells for later therapeutic transplantation (Dick
et al., 2001). Although these adult chimeras are not routinely
evaluated for human cell contribution to neurons, it is
conceivable that cells with this potential could be trans-
planted and thereby contribute to neural tissue in the adult.
The potential for variable outcomes certainly depends on the
donor stem cell source, level of purity of the donor cell
preparation, and plasticity of the cells in the target
environment. Whether this would occur in greater frequency
if cells were transplanted during embryogenesis is unknown,
but because this is not an obvious prediction of the
experimental outcomes, such studies would be legally
permitted until the data prove otherwise. This is just one
example of how analysis of human “tissue-specific” stem
cells in chimeras could lead to complicated legal challenges.
Specific guidelines regarding the permitted contribution to
total tissue and or cell subsets within a tissue will ultimately
be required.
A far greater challenge is the use of chimeric research to
develop safe and efficacious therapies to human disease
based on human ES cells or induced pluripotent stem cells
(iPS). Although these cells or their derivatives may have the
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their full potential is not easily evaluated without trans-
plantation into a permissive background, i.e., an embryonic
environment. Similarly, aside from blood and skin stem cells,
most other posnatal tissue stem cell types fail to proliferate
robustly in an adult environment, making it difficult to
evaluate their potential in adult tissues without knowing the
cues that govern their differentiation during embryogenesis.
Finally, knowledge of the efficacy and safety of these cells
long term (potential to form tumors over time, for example)
may be more easily addressed in embryonic and fetal
chimeras. These endeavors to learn the therapeutic poten-
tial of human cells represent the largest point of debate over
the influence of the Guidelines and the Act (for a detailed
scientific perspective on the ethics of human tissue
contributions to nonhuman embryos, see (Karpowicz et al.,
2004)).
Consequently, the Guidelines effectively ban the gener-
ation of any form of chimera or hybrid in either direction of
transfer, that is, from nonhuman to human or human to
nonhuman, at any stage of prenatal development. It is
interesting to note that while the Guidelines purport to
regulate the derivation and use of human stem cells in
research (Section 7 of the Guidelines (CIHR, 2007)); they also
prohibit the introduction of nonhuman cells into human
embryos and fetuses. However, no mention is made of the
introduction of nonhuman cells into postnatal human beings.
Noncompliance with the Guidelines could cause an institu-
tion to lose funding from the Agencies until it achieves
compliance (NSERC, 2008).
Table 1 summarizes the regulation of chimeras in
Canadian stem cell research by indicating the experiments
that are prohibited under the Act and the Guidelines. No
experiments that we are aware of have proposed the
introduction of animal cells into human embryos, but these
experiments would indeed be illegal in Canada. It is
interesting to note that this kind of experiment will now be
explicitly permitted in the United Kingdom, subject to
compliance with a regulatory regime (The Human Fertilisa-
tion and Embryology Act (United Kingdom. Human Fertilisa-
tion and Embryology Act, 2008) laying out this regulatory
scheme was adopted in November 2008). These differences
in regulations will likely result in such research activities
(and resulting publications) being restricted to locations
where the work is permitted.Table 1 Summary of the regulation of human–animal chimera re
Type a Animal → human
Embryo Fetus b Postn
The Act Prohibited Allowed Allow
The Guidelines Prohibited Prohibited Allow
a This refers to the way the chimera is made: by introducing animal c
each case at different stages of development.
b Although these combinations are not prohibited per se under the Act
of animal origin in human beings would be subject, inter alia, to the
c The Guidelines do not comment onwhether this possibility is either c
such an experiment should be reviewed by the SCOC, as only expe
technically subject to its review.
d The Guidelines state that this research is permissible to reconstitute
animals must not be used for reproductive purposes.Loopholes and exceptions created by the Canadian
regulatory scheme (largely by omission) produce a patchwork
of regulations to which scientists must adhere, which are
further complicated by restrictions dictated by funding and
not by law. No explicit legal prohibitions apply to the creation
of chimeras by introducing animal cells into a human fetus,
although this would not be in compliance with the Guidelines,
and therefore not permitted in laboratories funded by the
Agencies. In addition, experiments such as those of Fink et al.
(Fink et al., 2000), in which fetal pig neuronswere introduced
into the brains of patients with Parkinson’s disease and
Huntington’s disease, would not be regulated by either the
Act or the Guidelines. However, these experiments would be
subject to the Food and Drugs Act and its regulations
concerning clinical trials and other safety requirements.
Currently, experiments involving the introduction of
human stem cells into animals at early developmental
stages, such as those of Muotri et al. (Muotri et al., 2005),
would not be permitted in Canadian laboratories that receive
funds from the Agencies (or are attached to institutions that
receive funds from the Agencies), although they would
technically be legal in Canada. Experiments involving the
transfer of human stem cells into postnatal animals,
however, are permitted pursuant to the Guidelines (Section
8.1.6 (CIHR, 2007)), provided that they aim to reconstitute a
specific tissue or organ to derive a preclinical model, and
that the animals used in such experiments are not permitted
to reproduce. These experiments could provide less useful
information or models, as the integration of human stem
cells in postnatal animal tissues in this case may vary
according to developmental stage or environmental cues in
the host. The legal status of the resulting organisms,
including reproductive potential and protections, has not
been addressed. There are also no current standards
requiring researchers to assess specific tissue contribution
(neural and germline cells) as part of their experimental
programs, leaving this area to self regulation by the scientist.The Act as a potential avenue for further
regulation?
As the previous discussion illustrates, research in this area in
Canada is currently subject to different limitations depend-
ing on the sources of funding (Baylis, 2002). Section 11 of thesearch in Canada
Human → animal
atal b Embryo Fetus Postnatal
ed Allowed Allowed Allowed
ed c Prohibited Prohibited Allowed d
ells into a human or by introducing human cells into an animal, in
, and may be permitted under the Guidelines, the use of stem cells
Food and Drugs Act and its regulations concerning clinical trials.
ontrary to or in conformity with the Guidelines. It is unclear whether
riments involving the use of human embryonic stem cells are
a specific tissue or organ to derive a preclinical model, and that the
14 S. Bordet et al.Act has been proposed as a means to establish a single
national regulatory framework for human–animal combina-
tions which raise concerns (Baylis, 2002). Section 11 reads as
follows:
1. No person shall, except in accordance with the regula-
tions and a licence, combine any part or any proportion of
the human genome specified in the regulations with any
part of the genome of a species specified in the
regulations.
2. The following definitions apply in this section. qhuman
genomeq means the totality of the deoxyribonucleic acid
sequence of the human species. qspeciesq means any
taxonomic classification of nonhuman life.
Although ostensibly addressing transgenic animals, one
author has speculated that, depending on the meaning
ascribed to the word qcombineq in Section 11, it could be
used to govern combinations of the human genome with that
of other species obtained by mixing human and animal
gametes, by interspecies nuclear transfer, or by creating
beings with human and animal cells within one organism.
This leaves the power of regulation open to interpretation of
the individual or group charged with its execution.
No regulations have been adopted pursuant to Section 11
at the time of preparation of this document, leaving it of no
effect for the moment. In addition, recent developments
may prevent its use as a tool for the regulation of any type of
human–animal mixtures.The constitutional challenge to controlled activities
The Québec Court of Appeal recently declared several
provisions of the Act, including Section 11, unconstitutional.
A large portion of the regulatory regime that the Act sought
to establish has been declared unconstitutional as well,
including the regulation and licensing system put in place by
the Act for those who carry out various qcontrolled activitiesq
in connection with human reproduction, such as the
creation, storage, and manipulation of human embryos in
vitro, as well as the provisions that create and empower the
Assisted Human Reproduction Agency to license and oversee
these activities. The prohibitions of the Act concerning the
creation of chimeras by introducing foreign cells into human
embryos, however, were not challenged in this case. The
judgment was appealed to the Supreme Court of Canada,
which heard the case in April 2009 (Case No. 32750). Neither
the decision nor possible changes to the Act have yet been
made public. If Section 11 is also found to be unconstitutional
at this level, it will be of no force and effect. In such a case,
any national regulatory scheme for experiments creating
transgenic animals, human–animal chimeras, and hybrids for
research would have to be based on a different mechanism,
and could require the consent or cooperation of each
province to be implemented.
The constitutional difficulty of establishing a national
regulatory system in Canada may have the effect of
reinforcing the existing prohibitions. Where a unified
national regulatory regime seems difficult to achieve,
Parliament may be tempted to leave prohibitions in place
to set minimal enforceable limits to research, rather thanattempting to establish regulations that will not withstand
constitutional scrutiny. It is interesting to note that the
criminal prohibitions contained in the Act were not chal-
lenged as unconstitutional, whereas the regulatory regime
aimed at controlled activities was. The Supreme Court
decision will therefore reveal whether the federal govern-
ment can hope to wield more subtle tools than prohibitions in
its attempts to regulate the field of research with human
reproductive material.International challenges regulating chimera and
hybrid stem cell research
Uniform regulation for chimera research has been achieved
by the United Kingdom, which has chosen a fairly permissive
but controlled approach, where research is monitored
through a licensing system. Certain controversial experi-
ments with human admixed embryos are permitted, includ-
ing chimeras made by introducing cells of animal origin into
human fetuses, subject to licensing by a central authority
(United Kingdom. Human Fertilisation and Embryology Act,
2008). The creation of chimeras by introducing human cells
into animals is governed by legislation dealing with animal
experimentation in general, which also requires a license for
experiments made on protected animals (United Kingdom.
Animal (Scientific Procedures) Act, 1986).
However, the balance between absolute restriction or
legality of research activities, and regulation of activities
by funding or other agencies, remains a challenge faced by
many countries, and is made more acute by the issues
raised by stem cell research itself. In the United States,
the difficulty of achieving political consensus on stem cell-
related issues has led to a sharp difference between the
regulation of federally funded research and privately
funded research in this area. New guidelines aimed at
“removing barriers to responsible conduct of research using
embryonic stem cells” were recently released by the
National Institutes of Health in the United States (United
States. Executive Order No. 13505, 2009; National Insti-
tutes of Health. United States. National Institutes of Health
Guidelines on Human Stem Cell Research, 2009, lifting of
some previous restrictions on federally funded stem cell
research and enforcing others. Some aspects of chimeras
are explicitly dealt with: the introduction of human
embryonic stems cells or human iPS cells into primate
blastocysts and the breeding of animals in which such
introduced cells may contribute to the germ line are both
prohibited. There is no further explicit guidance on
chimera experiments in these guidelines. However, be-
cause the “Dickey Amendment,” which bans the use of
federal funds in research that involves the destruction of
human embryos, remains in place (United States. Omnibus
Appropriations Act, 2009), federal funds may not be used
to create embryos into which animal material is intro-
duced, since such an embryo would be destroyed. Several
proposed bills aimed at permitting the derivation of human
stem cells from certain human embryos (“surplus” embryos
resulting from IVF) are currently before Congress (United
States. Stem Cell Research Enhancement Act of 2009, S.
487, Congr., 2009), but these bills do not directly address
the creation of chimeric human embryos.
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have failed to be passed in the U.S. Congress (United States.
Human Chimera Prohibition Act of 2005, S. 659 109th Congr.,
2005). Another bill with this goal was introduced in the
Senate in the summer of 2009 (United States. Human-Animal
Hybrid Prohibition Act of 2009, S. 1435 111th Congr., 2009).
In the absence of federal legislation dealing with chimeras,
privately funded chimeric research is not directly regulated
unless a state adopts relevant legislation, encouraging a
patchwork of laws and limitations at federal, funding, and
state levels.
Australia has attempted to establish a single regime
applicable to research with human embryos through the
adoption of an intergovernmental agreement (Australia.
Intergovernmental Agreement on Research Involving Human
Embryos and Prohibition of Human Cloning, 2004), which
requires state governments to pass legislation mirroring
federal statute on this point. This legislation was recently
amended to explicitly prohibit chimeric embryos but to
permit hybrid embryos in specific cases (Australia. Prohibi-
tion of Human Cloning for Reproduction and the Regulation
of Human Embryo Research Amendment Act, 2006); howev-
er, not all states followed with passage of the legislation at
the same rate, and one state has so far failed to do so (Then,
2009; Western Australia. Human Reproductive Technology
Amendment Bill, 2007).
In distinct contrast to the debate in other countries,
legislation and guidelines passed in Israel in 1999 and 2001
prohibiting generation of embryos explicitly for research
purposes or implantation of human embryos resulting from
somatic cell nuclear transfer (defined as human cloning)
(Prohibition of Genetic Intervention (Human Cloning and
Genetic Manipulation of Reproductive Cells) Law, SH 1697,
1999; Bioethics Advisory Committee of the Israel Academy of
Sciences and Humanities. Report on the Use of Embryonic
Stem Cells for Therapeutic Research, 2001) reflect differing
social and religious views regarding the moral status of
embryos (Gross and Ravitsky, 2003). Recognized as world
leaders and prolific authors in stem cell research (Gretchen,
2002), Israel has both permissive laws and government
financial support for generation of ES cell lines and
subsequent experimental investigation. However, the issue
of hybrid and chimera generation or research has not
specifically been addressed (Simonstein, 2008).
Given the difficulty of achieving uniform regulation, even
within countries, voluntary guidelines and reports published
by bodies such as the National Academy of Sciences in the
United States (National Research Council and Institute of
Medicine, 2007)and the International Society for Stem Cell
Research (Hyun et al., 2007) play an important international
role by providing guidance, and informed contributions to
the societal and legislative debate. The evolving laws and
guidelines will be met with both support and opposition as
scientists and other stakeholders work toward a regulatory
framework which is ethical, scientifically feasible, and
keeping in time with advancing technology.Role of the funding agency
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